NAOV NanoVibronix, Inc. logo

NAOV NanoVibronix, Inc.

Healthcare
$1.90+1.06%ClosedMarket Cap: $1.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.10

P/S

0.51

EV/EBITDA

-0.00

DCF Value

$-109.85

FCF Yield

-1117.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

-12.4%

Operating Margin

-623.3%

Net Margin

-744.2%

ROE

-43.7%

ROA

-40.7%

ROIC

-39.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$653.0K$-3.8M$
Q4 null$312.0K$-16.0M$
FY null$2.6M$-18.2M$
Q3 null$722.0K$510.0K$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Murphy Brian Mdirector, officer: Chief Executive Officer
SellFri Jan 03
Schroeder Mariadirector
SellThu Jan 02
MIKA THOMASdirector
SellThu Jan 02
JACOB HAROLDdirector, officer: Chief Medical Officer
SellThu Jan 02
Goldstein Martin Mdirector
SellThu Jan 02

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

2.06

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

Peers